NewAmsterdam Pharma (NASDAQ:NAMS) CEO Michael Davidson Sells 58,253 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 58,253 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $35.30, for a total transaction of $2,056,330.90. Following the transaction, the chief executive officer owned 459,859 shares of the company’s stock, valued at approximately $16,233,022.70. The trade was a 11.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $34.28 on Friday. The firm has a market cap of $3.89 billion, a PE ratio of -19.81 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The business’s 50 day moving average price is $34.05 and its two-hundred day moving average price is $32.88.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. Research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of NewAmsterdam Pharma in the first quarter worth approximately $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of NewAmsterdam Pharma by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after acquiring an additional 34,563 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in NewAmsterdam Pharma during the 2nd quarter worth about $212,000. Bank of New York Mellon Corp acquired a new position in NewAmsterdam Pharma during the second quarter valued at $6,392,000. Finally, Geode Capital Management LLC grew its stake in shares of NewAmsterdam Pharma by 15.9% during the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after purchasing an additional 13,629 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NAMS shares. Leerink Partners restated an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. Guggenheim upped their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. The Goldman Sachs Group upped their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Royal Bank Of Canada increased their price target on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Finally, Stifel Nicolaus increased their target price on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and an average target price of $46.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.